Anteris Technologies Global Corp (AVR) Stock Price, Quote & News

Company Profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bios...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 61 7 3152 3200

Website: anteristech.com

Address:

Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong, Australia

Wooyongjin Dec. 1 at 4:33 AM

$AVR I think there will be some pumping / sec

0 · Reply

Wooyongjin Nov. 24 at 2:50 PM

$AVR It's strong today

0 · Reply

SouthHaus Nov. 18 at 11:17 AM

$AVR AGHHHHH!!! Down almost 16%… On TWO shares.

1 · Reply

OliverBroderick Nov. 13 at 6:47 PM

$AVR L1 wouldn't have double down on financing their latest round for $4.9 per share if they didn't beleive. Largest Inst. Owner before BlackRock, who recently took a 5% stake. So undervalued.

2 · Reply

BearTwitter Nov. 13 at 4:38 PM

$AVR Why is it trading so far under analysts PT's, almost 4x lower than the average analyst PT. Also, Blackrock/big institutional players bought in for 25% higher. This is way too cheap

0 · Reply

BearTwitter Nov. 13 at 4:17 PM

$AVR This is way too cheap. Drops 6% on no news, earnings were positive, slowed burn rate, promising trials, big institutional investors bought in, no reason for this to be anywhere under $5.

0 · Reply

OliverBroderick Nov. 13 at 4:14 PM

$AVR Blackrock also bought in on October 17th for 4.9 a share, which is also a 25% discount. L1 and other big hedge funds last round paid $4.9 a share. Why do people think they know better than these big institutions, so undervalued.

0 · Reply

OliverBroderick Nov. 13 at 4:05 PM

$AVR Why is the Australian ticker trading at 6% premium. This stock makes no sense

0 · Reply

d_risk Nov. 12 at 10:00 PM

$AVR - Anteris Technologies Global Corp. - 10Q - Updated Risk Factors No substantial changes. The only update: regulatory approval for the PARADIGM Trial could be revoked, the study may fail, and FDA PMA for DurAVR is not guaranteed. #MedicalDevices #HealthcareTechnology #FDAApproval #ClinicalTrials #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/AVR/10-Q/2025-11-12

0 · Reply

Sterling_Prescott Nov. 12 at 3:54 PM

$AVR Taking another look, don't understand how it can be down 20%+ after announcing they are starting their pivotal trial. No position, but makes no sense. Especially considering pivotal trial was on main pipeline candidate, which is big deal/shows they are advancing

0 · Reply

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Nov 12, 2025, 5:52 PM EST - 25 days ago

Anteris Announces Results for the Third Quarter of 2025

Oct 27, 2025, 5:43 PM EDT - 5 weeks ago

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Oct 27, 2025, 8:43 AM EDT - 5 weeks ago

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Sep 19, 2025, 2:30 AM EDT - 2 months ago

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Sep 11, 2025, 8:50 AM EDT - 3 months ago

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Aug 11, 2025, 4:52 PM EDT - 4 months ago

Anteris Announces Results for the Second Quarter of 2025

Jun 9, 2025, 10:52 PM EDT - 6 months ago

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Mar 31, 2025, 7:15 AM EDT - 9 months ago

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Mar 21, 2025, 7:30 AM EDT - 9 months ago

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Mar 12, 2025, 8:33 PM EDT - 9 months ago

Anteris Reports 2024 Financial Results and Provides Corporate Update

Dec 16, 2024, 7:49 PM EST - 1 year ago

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Dec 12, 2024, 10:34 PM EST - 1 year ago

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

Dec 9, 2024, 7:43 AM EST - 1 year ago

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

Nov 22, 2024, 1:54 PM EST - 1 year ago

Cardiac device maker Anteris Technologies files for $75M IPO

Nov 22, 2024, 12:09 PM EST - 1 year ago

Australian medical device company Anteris Technologies Global files for a $75 million US IPO

Nov 22, 2024, 11:09 AM EST - 1 year ago

Anteris Technologies Global IPO Registration Document (S-1)

Wooyongjin Dec. 1 at 4:33 AM

$AVR I think there will be some pumping / sec

0 · Reply

Wooyongjin Nov. 24 at 2:50 PM

$AVR It's strong today

0 · Reply

SouthHaus Nov. 18 at 11:17 AM

$AVR AGHHHHH!!! Down almost 16%… On TWO shares.

1 · Reply

OliverBroderick Nov. 13 at 6:47 PM

$AVR L1 wouldn't have double down on financing their latest round for $4.9 per share if they didn't beleive. Largest Inst. Owner before BlackRock, who recently took a 5% stake. So undervalued.

2 · Reply

BearTwitter Nov. 13 at 4:38 PM

$AVR Why is it trading so far under analysts PT's, almost 4x lower than the average analyst PT. Also, Blackrock/big institutional players bought in for 25% higher. This is way too cheap

0 · Reply

BearTwitter Nov. 13 at 4:17 PM

$AVR This is way too cheap. Drops 6% on no news, earnings were positive, slowed burn rate, promising trials, big institutional investors bought in, no reason for this to be anywhere under $5.

0 · Reply

OliverBroderick Nov. 13 at 4:14 PM

0 · Reply

OliverBroderick Nov. 13 at 4:05 PM

$AVR Why is the Australian ticker trading at 6% premium. This stock makes no sense

0 · Reply

d_risk Nov. 12 at 10:00 PM

0 · Reply

Sterling_Prescott Nov. 12 at 3:54 PM

0 · Reply

Sterling_Prescott Nov. 11 at 9:13 PM

$AVR Why so undervalued? Lost 12% in a week for no reason? PT are 3 and 4x value. Looks like decent buy/value, no position here.

0 · Reply

Wooyongjin Nov. 6 at 9:59 PM

$AVR When will you pump? Are there any new issues?

0 · Reply

GuadalupeBono252 Nov. 4 at 4:37 PM

$AVR advances its position in tech development while market demand for automation grows as AITX adds a major U.S. healthcare system client, moving from pilot to paid deployments as hospitals adopt RIO 360 units to enhance safety and efficiency.

0 · Reply

PaulBEquity Nov. 3 at 4:00 PM

$AVR significantly undervalued.. TD, Barclays, Cantor, Lake Street all reputable names

0 · Reply

DillowWesgreaves Nov. 3 at 12:31 PM

$AVR Undervalued... Nice pipeline, went down significantly since announced start of pivotal trial phase, have seen some stocks go up 50-70% when announcing this, (humacyte, apellis, etc). Will be up and on from here

0 · Reply

StockScanners Nov. 1 at 6:30 PM

$AVR reached 4.75

0 · Reply

sk7777777 Oct. 30 at 9:09 PM

$AVR

0 · Reply

Goldenpoint9 Oct. 30 at 11:04 AM

$AVR

0 · Reply

jagstox Oct. 29 at 10:41 PM

$AVR Pure manipulation by Wal St "Institution" Ba4turds"...They stole some more shares from Retail!

0 · Reply

OliverBroderick Oct. 29 at 3:40 PM

$AVR still undervalued, pivotal trial phase is a big deal, seen 50-70% moves on pivotal trial phase starting for appelis, humacyte, iRhythm and their TAM wasn't $10B. Liking vertical integration with factory development, still think should be far north of $6, shouldn't be down 15%+ this week on all positive news

0 · Reply

jdlman Oct. 28 at 10:29 PM

$AVR any news here?

0 · Reply

RAIK7 Oct. 28 at 10:16 PM

$AVR https://www.stocktitan.net/news/AVR/anteris-dur-avr-thv-demonstrates-favorable-hemodynamics-in-small-5l6a14c3fyid.html

0 · Reply

Market Cap	192.40M
Revenue (ttm)	2.70M
Net Income (ttm)	-76.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,825.56%
Debt to Equity Ratio	0.04

Volume	81,000
Avg Vol	216,124
Day's Range	N/A - N/A
Shares Out	41.20M
Stochastic %K	92%
Beta	N/A
Analysts	Strong Sell
Price Target	$16.50